Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/7/2025

Switching Between SNRIs and SSRIs in Bipolar Disorder

Critical Recommendations

  • The American Academy of Child and Adolescent Psychiatry recommends avoiding combining multiple serotonergic agents due to serotonin syndrome risk, which can manifest within 24-48 hours with mental status changes, neuromuscular hyperactivity, and autonomic instability 2
  • The American Academy of Child and Adolescent Psychiatry suggests that paroxetine, fluvoxamine, and sertraline are associated with discontinuation syndrome characterized by dizziness, fatigue, myalgias, nausea, anxiety, and sensory disturbances 2
  • The American Academy of Child and Adolescent Psychiatry advises that abrupt discontinuation of shorter-acting SSRIs can trigger withdrawal symptoms 2
  • The Praxis Medical Insights guideline recommends that treatment with any antidepressant should be avoided in patients with a history of bipolar disorder unless combined with a mood stabilizer due to the risk of triggering manic episodes 1
  • The Praxis Medical Insights guideline suggests that mood stabilizers, such as lithium or valproate, should be the foundation of treatment in all phases of bipolar disorder 1
  • The Praxis Medical Insights guideline recommends monitoring within 1-2 weeks of any medication change 1
  • The Praxis Medical Insights guideline advises baseline and regular laboratory monitoring, including complete blood count, thyroid function, and kidney function tests for lithium, and liver function tests for valproate 1
  • The Praxis Medical Insights guideline suggests modifying treatment if there is not an adequate response within 6-8 weeks 1
  • The European Heart Journal recommends considering baseline ECG if cardiac risk factors are present 3
  • The European Heart Journal suggests that citalopram may cause QT prolongation at daily doses exceeding 40 mg/d and should be avoided in patients with long QT syndrome 2
  • The Journal of the American Academy of Child and Adolescent Psychiatry advises that SNRIs showed no association with cardiac arrest in registry studies, whereas SSRIs showed increased risk (OR 1.21) 3
  • The Journal of the American Academy of Child and Adolescent Psychiatry recommends that citalopram/escitalopram have the least effect on CYP450 isoenzymes and lower propensity for drug interactions 2
  • The Journal of the American Academy of Child and Adolescent Psychiatry suggests that fluoxetine, paroxetine, and sertraline may interact with drugs metabolized by CYP2D6 2
  • The Journal of the American Academy of Child and Adolescent Psychiatry advises that fluvoxamine has extensive interactions with multiple CYP enzymes (1A2, 2C19, 2C9, 3A4, 2D6) 2

Practical Switching Protocol

  • The Praxis Medical Insights guideline recommends confirming diagnosis is truly bipolar (not unipolar depression with anxiety) 1
  • The Praxis Medical Insights guideline suggests initiating or optimizing lithium to therapeutic levels (0.6-1.2 mEq/L) 1
  • The Praxis Medical Insights guideline advises waiting 1-2 weeks to ensure mood stabilizer is effective 1
  • The Journal of the American Academy of Child and Adolescent Psychiatry recommends beginning SNRI taper over 2-4 weeks depending on half-life 2
  • The Journal of the American Academy of Child and Adolescent Psychiatry suggests introducing SSRI at low dose (preferably citalopram/escitalopram for fewer interactions) 2
  • The Journal of the American Academy of Child and Adolescent Psychiatry advises monitoring closely for switching symptoms in first 24-48 hours after each dose change 2
  • The Journal of the American Academy of Child and Adolescent Psychiatry recommends titrating SSRI slowly over 1-2 week intervals 2
  • The Praxis Medical Insights guideline suggests reassessing need for continued antidepressant therapy at 6-8 weeks 1

REFERENCES

2

Management of Bipolar Disorder [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025